Roche's feud with NICE deepens over Kadcyla backbiting
This article was originally published in Scrip
Tensions between a health technology appraisal body and a single pharmaceutical company have rarely been higher than those between NICE and Roche. Not for the first time, Roche has lashed out at the UK's drug watchdog, this time over NICE's rejection of breast cancer drug Kadcyla (trastuzumab emtansine). But more unusually, NICE is biting back.